Session-aware quotes · provider delays vary · Not financial advice
NeutralLOW severityTech & AI18d ago

Novavax expects $235M-$275M in 2026 adjusted total revenue while targeting $150M-$200M in 2028 non-GAAP R&D and SG&A

Reported by Seeking Alpha · seekingalpha.com · August 6, 2026

$NVAX
Neutral read

What the tape says

What to watch: Monitor chip inventory cycles — overhang periods precede sharp upside moves in semis.

Amount
$235 million
Amount
$275 million
Amount
$150 million
Amount
$200 million

Market reaction today: $NVAX -0.89%

Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish Seeking Alpha's reporting.

Your read

Discussion

No one has weighed in yet. Start the discussion on this story.

More coverage on these names

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.